Search
FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement
We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).
Read moreMulti-center acute myeloid leukemia study update, December 2023
A project update from Prof Maria Teresa Voso. We successfully completed the data collection and harmonization phases, and are now in the process of data analysis.
Read moreSplenic marginal zone lymphoma study update, February 2024
A project update from Dr Ahmed Ludvigsen Al-Mashhadi. I am truly grateful for this opportunity provided by EHA, and for EHA's effort in advancing research in a field that may otherwise be very difficult to explore.
Read moreEHA-SRH-SHTRM Balkan Hematology Tutorial 2023
EHA is joining forces with the Societatea Românã de Hematologie (SRH) and Scientific and Practical Society of Hematologists and Transfusiologists from the Republic of Moldova (SHTRM) to organize the EHA-SRH-SHRTM Balkan Hematology Tutorial.
Read moreSWG Educational Activities
2023 meetingsThe following EHA-SWG meetings took place in the past calendar year:
54th General Assembly of ERIC members at ELN Symposium 2023
Mannheim, Germany
April 18, 2023
ERIC/Brazilian CLL Group workshop on biomarkers in CLL
Brasilia, Brazil
May 25–26, 2023
55th General Assembly of ERIC members at…